AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024.
“Since the NuVasive merger closed in September of last year, we worked aggressively to execute our integration strategy and are making significant progress towards rapidly reaching steady state. I am pleased with the first quarter results delivered by strong teamwork and partnership throughout our organization. Surgeons and hospitals are responding favorably to our best-in-class product offering of clinically advanced devices and enabling technologies and worldwide sales reflect the long-term potential of our company,” said Dan Scavilla, President and Chief Executive Officer. “We are pleased with the engagement and retention levels of our surgeon customers and sales force and continue to see great opportunities to improve patient care. We are now one company with one galvanizing mission of being the most innovative musculoskeletal technology company in the world. I believe the potential for Globus has never been greater, as we continue to redefine surgery with procedural solutions built around enabling technology.”
“Our first quarter was focused on driving salesforce retention and alignment, process standardization and delivering on actions to improve operating efficiencies moving ahead, while achieving planned cost synergies,” commented Keith Pfeil, COO-CFO. “As we are now almost nine months into operating as a combined company, I am pleased to see us executing against our integration objectives and realizing the early stages of our vision. We continue to be well positioned in delivering against our commitments for the year.”
Worldwide net sales for the first quarter of 2024 were $606.7 million, an as-reported increase of 119.3% over the first quarter of 2023. U.S. net sales for the first quarter of 2024 increased by 106.3% compared to the first quarter of 2023. International net sales increased by 190.7% over the first quarter of 2023 on an as-reported basis, and an increase of 194.1% on a constant currency basis. Net Sales increases were driven by the addition of NuVasive, as well as increased volume of spine product sales and enabling technology products and services.
GAAP net loss for the first quarter of 2024 was $7.1 million, a decrease of 114.5% over the same period in the prior year. Diluted EPS for the first quarter was ($0.05), compared to $0.48 for the first quarter of 2023. The GAAP net loss was primarily driven by the amortization costs of purchase-accounting-related fair-value step ups and restructuring costs. Non-GAAP diluted EPS for the first quarter of 2024, which excludes, among other costs, both acquisition related and restructuring costs, was $0.72, compared to $0.53 in the first quarter of 2023, an increase of 36.4%.
Net cash provided by operating activities was $52.4 million, and non-GAAP free cash flow was $23.8 million for the first quarter of 2024.
2024 Annual Guidance
The Company today updated its guidance for full year 2024 revenue in the range of $2.460 to $2.485 billion, and non-GAAP fully diluted earnings per share in the range of $2.75 to $2.85. This updated guidance is an increase over the prior full year 2024 revenue guidance of $2.450 to $2.475 billion, and non-GAAP fully diluted earnings per share guidance of $2.68 to $2.70.
Conference Call Information
Globus Medical will hold a teleconference to discuss its first quarter 2024 results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news-events/events-webcasts.
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.
About Globus Medical, Inc.
Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.
Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, acquisition of in-process research and development, merger and acquisition related costs/licensing, restructuring related costs, certain foreign currency acquisition-related impacts, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs/licensing represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees, as well as one-time licensing fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, and costs associated with consolidating facilities. Acquisition of in-process research and development represents the expensing of acquired assets with no alternative future use and related fees. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.
In addition, for the period ended March 31, 2024 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition of in-process research and development, merger and acquisition related costs/licensing, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, the impact of dilution attributable to the Convertible Notes, and the tax effects of all of the foregoing adjustments. We also present Non-GAAP gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends. Additionally, for the period ended March 31, 2024 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.
Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow and constant currency net sales growth are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow and constant currency net sales growth may differ from that of other companies and therefore may not be comparable.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive business and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
| Three Months Ended | |||||
| March 31, | |||||
| (In thousands, except per share amounts) | 2024 | 2023 | |||
| Net sales | $ | 606,666 | $ | 276,688 | |
| Cost of sales | 241,487 | 70,825 | |||
| Gross profit | 365,179 | 205,863 | |||
| Operating expenses: | |||||
| Research and development | 57,268 | 21,082 | |||
| Selling, general and administrative | 248,710 | 122,416 | |||
| Provision for litigation, net | (31 | ) | — | ||
| Amortization of intangibles | 29,676 | 4,601 | |||
| Acquisition-related costs | 2,418 | 1,361 | |||
| Restructuring Costs | 19,141 | — | |||
| Total operating expenses | 357,182 | 149,460 | |||
| Operating income/(loss) | 7,997 | 56,403 | |||
| Other income/(expense), net | |||||
| Interest income/(expense), net | (1,894 | ) | 6,497 | ||
| Foreign currency transaction gain/(loss) | (15,371 | ) | 212 | ||
| Other income/(expense) | 710 | 77 | |||
| Total other income/(expense), net | (16,555 | ) | 6,786 | ||
| Income/(loss) before income taxes | (8,558 | ) | 63,189 | ||
| Income tax provision/(benefit) | (1,441 | ) | 14,060 | ||
| Net income/(loss) | $ | (7,117 | ) | $ | 49,129 |
| Other comprehensive income/(loss), net of tax: | |||||
| Unrealized gain/(loss) on marketable securities | 379 | 4,298 | |||
| Foreign currency translation gain/(loss) | (1,232 | ) | 910 | ||
| Total other comprehensive income/(loss), net of tax | (853 | ) | 5,208 | ||
| Comprehensive income/(loss) | $ | (7,970 | ) | $ | 54,337 |
| Earnings per share: | |||||
| Basic | $ | (0.05 | ) | $ | 0.49 |
| Diluted | $ | (0.05 | ) | $ | 0.48 |
| Weighted average shares outstanding: | |||||
| Basic | 135,358 | 100,279 | |||
| Diluted | 135,358 | 102,196 | |||
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
| March 31, | December 31, | |||||||
| (In thousands, except share and per share values) | 2024 | 2023 | ||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 354,062 | $ | 467,292 | ||||
| Short-term marketable securities | 80,408 | 50,497 | ||||||
| Accounts receivable, net of allowances of $11,527 and $8,934, respectively | 534,333 | 503,235 | ||||||
| Inventories | 816,196 | 848,135 | ||||||
| Prepaid expenses and other current assets | 43,209 | 44,580 | ||||||
| Income taxes receivable | 366 | 1,635 | ||||||
| Total current assets | 1,828,574 | 1,915,374 | ||||||
| Property and equipment, net of accumulated depreciation of $447,122 and $425,695, respectively | 578,887 | 586,932 | ||||||
| Operating lease right of use assets | 56,347 | 59,931 | ||||||
| Long-term marketable securities | 51,256 | 75,428 | ||||||
| Intangible assets, net | 888,208 | 924,603 | ||||||
| Goodwill | 1,451,106 | 1,434,540 | ||||||
| Other assets | 78,216 | 78,590 | ||||||
| Deferred income taxes | 11,018 | 10,685 | ||||||
| Total assets | $ | 4,943,612 | $ | 5,086,083 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 50,487 | $ | 56,671 | ||||
| Accrued expenses | 210,011 | 240,460 | ||||||
| Operating lease liabilities | 11,749 | 11,967 | ||||||
| Income taxes payable | 43,058 | 3,845 | ||||||
| Senior convertible notes | 424,044 | — | ||||||
| Business acquisition liabilities | 29,649 | 61,035 | ||||||
| Deferred revenue | 17,077 | 18,369 | ||||||
| Payable to broker | 249 | — | ||||||
| Total current liabilities | 786,324 | 392,347 | ||||||
| Business acquisition liabilities, net of current portion | 81,661 | 78,323 | ||||||
| Operating lease liabilities | 89,809 | 91,037 | ||||||
| Senior convertible notes | — | 417,400 | ||||||
| Deferred income taxes and other tax liabilities | 39,952 | 84,421 | ||||||
| Other liabilities | 23,505 | 24,596 | ||||||
| Total liabilities | 1,021,251 | 1,088,124 | ||||||
| Equity: | ||||||||
| Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 112,626,136 and 113,905,565 shares at March 31, 2024 and December 31, 2023, respectively | 113 | 114 | ||||||
| Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares at March 31, 2024 and December 31, 2023, respectively | 22 | 22 | ||||||
| Additional paid-in capital | 2,886,436 | 2,870,749 | ||||||
| Accumulated other comprehensive income/(loss) | (11,045 | ) | (10,192 | ) | ||||
| Retained earnings | 1,046,835 | 1,137,266 | ||||||
| Total equity | 3,922,361 | 3,997,959 | ||||||
| Total liabilities and equity | $ | 4,943,612 | $ | 5,086,083 | ||||
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| (In thousands) | 2024 | 2023 | ||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | (7,117 | ) | $ | 49,129 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Acquired in-process research and development | 12,613 | — | ||||||
| Depreciation and amortization | 55,261 | 18,108 | ||||||
| Amortization of premiums on marketable securities | 24 | 482 | ||||||
| Provision for excess and obsolete inventory | 3,914 | 2,055 | ||||||
| Amortization of inventory fair value step up | 53,670 | — | ||||||
| Amortization of 2025 Note fair value step up | 6,658 | — | ||||||
| Stock-based compensation expense | 17,260 | 8,953 | ||||||
| Allowance for doubtful accounts | 2,968 | 810 | ||||||
| Change in fair value of business acquisition liabilities | (165 | ) | (446 | ) | ||||
| Change in deferred income taxes | (45,091 | ) | (3,979 | ) | ||||
| (Gain)/loss on disposal of assets, net | 34 | 81 | ||||||
| Payment of business acquisition-related liabilities | (16,115 | ) | (772 | ) | ||||
| Net (gain)/loss from foreign currency adjustment | 11,191 | — | ||||||
| (Increase) decrease in: | ||||||||
| Accounts receivable | (36,393 | ) | (9,861 | ) | ||||
| Inventories | (8,986 | ) | (22,470 | ) | ||||
| Prepaid expenses and other assets | 1,778 | 836 | ||||||
| Increase (decrease) in: | ||||||||
| Accounts payable | (5,753 | ) | 3,916 | |||||
| Accrued expenses and other liabilities | (33,881 | ) | (9,969 | ) | ||||
| Income taxes payable/receivable | 40,517 | 16,440 | ||||||
| Net cash provided by/(used in) operating activities | 52,387 | 53,313 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchases of marketable securities | (8,017 | ) | (69,141 | ) | ||||
| Maturities of marketable securities | 85 | 85,546 | ||||||
| Sales of marketable securities | 2,565 | 13,240 | ||||||
| Purchases of property and equipment | (28,568 | ) | (15,991 | ) | ||||
| Acquisition of businesses, net of cash acquired and purchases of intangible and other assets | (12,649 | ) | (2,662 | ) | ||||
| Net cash provided by/(used in) investing activities | (46,584 | ) | 10,992 | |||||
| Cash flows from financing activities: | ||||||||
| Payment of business acquisition-related liabilities | (30,475 | ) | (1,919 | ) | ||||
| Net proceeds from exercise of stock options | 3,413 | 4,859 | ||||||
| Payments related to tax withholdings for share-based compensation | (5,343 | ) | — | |||||
| Repurchase of common stock | (83,316 | ) | — | |||||
| Net cash provided by/(used in) financing activities | (115,721 | ) | 2,940 | |||||
| Effect of foreign exchange rates on cash | (3,312 | ) | (26 | ) | ||||
| Net increase/(decrease) in cash and cash equivalents | (113,230 | ) | 67,219 | |||||
| Cash and cash equivalents at beginning of period | 467,292 | 150,466 | ||||||
| Cash and cash equivalents at end of period | $ | 354,062 | $ | 217,685 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Income taxes paid, net | $ | 1,967 | $ | 1,724 | ||||
| Non-cash investing and financing activities: | ||||||||
| Accrued purchases of property and equipment | $ | 5,426 | $ | 6,493 | ||||
Supplemental Financial Information
Net Sales by Product Category:
| Three Months Ended | ||||||
| March 31, | ||||||
| (In thousands) | 2024 | 2023 | ||||
| Musculoskeletal Solutions | $ | 574,697 | $ | 251,607 | ||
| Enabling Technologies | 31,969 | 25,081 | ||||
| Total net sales | $ | 606,666 | $ | 276,688 | ||
Liquidity and Capital Resources:
| March 31, | December 31, | |||||
| (In thousands) | 2024 | 2023 | ||||
| Cash and cash equivalents | $ | 354,062 | $ | 467,292 | ||
| Short-term marketable securities | 80,408 | 50,497 | ||||
| Long-term marketable securities | 51,256 | 75,428 | ||||
| Total cash, cash equivalents and marketable securities | $ | 485,726 | $ | 593,217 | ||
The following tables reconcile GAAP to Non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
| Three Months Ended | |||||||
| March 31, | |||||||
| (In thousands, except percentages) | 2024 | 2023 | |||||
| Net income/(loss) | $ | (7,117 | ) | $ | 49,129 | ||
| Interest (income)/expense, net | 1,894 | (6,497 | ) | ||||
| Provision for income taxes | (1,441 | ) | 14,060 | ||||
| Depreciation and amortization | 55,261 | 18,109 | |||||
| EBITDA | 48,597 | 74,801 | |||||
| Stock-based compensation expense | 12,439 | 8,953 | |||||
| Provision for litigation, net | (31 | ) | — | ||||
| Merger and acquisition-related costs/licensing | 56,387 | 1,375 | |||||
| Acquisition of in-process research and development | 12,613 | — | |||||
| Net (gain) loss from strategic investments | 223 | — | |||||
| Non-cash acquisition-related foreign currency impacts | 11,191 | — | |||||
| Restructuring costs | 25,162 | — | |||||
| Adjusted EBITDA | $ | 166,581 | $ | 85,129 | |||
| Net income/(loss) as a percentage of net sales | -1.2 | % | 17.8 | % | |||
| Adjusted EBITDA as a percentage of net sales | 27.5 | % | 30.8 | % | |||
Non-GAAP Net Income Reconciliation Table:
| Three Months Ended | |||||||
| March 31, | |||||||
| (In thousands) | 2024 | 2023 | |||||
| Net income/(loss) | $ | (7,117 | ) | $ | 49,129 | ||
| Provision for litigation, net | (31 | ) | — | ||||
| Amortization of intangibles | 29,676 | 4,601 | |||||
| Merger and acquisition-related costs/licensing | 56,387 | 1,375 | |||||
| Acquisition of in-process research and development | 12,613 | — | |||||
| Non-cash acquisition-related foreign currency impacts | 11,191 | — | |||||
| Restructuring Costs | 25,162 | — | |||||
| Net gain/(loss) on strategic investments | 223 | — | |||||
| Tax effect of adjusting items | (30,006 | ) | (1,329 | ) | |||
| Non-GAAP net income/(loss) | $ | 98,098 | $ | 53,776 | |||
Non-GAAP Gross Profit Reconciliation Table:
| Three Months Ended | |||||||
| March 31, | |||||||
| (In thousands) | 2024 | 2023 | |||||
| Cost of sales | $ | 241,487 | $ | 70,825 | |||
| Merger and acquisition related costs/licensing | (53,670 | ) | (1,361 | ) | |||
| Adjusted cost of sales | $ | 187,817 | $ | 69,464 | |||
| Adjusted gross profit | $ | 418,849 | $ | 207,224 | |||
| Adjusted gross profit as a percentage | 69.0 | % | 74.9 | % | |||
Non-GAAP Diluted Earnings Per Share Reconciliation Table:
| Three Months Ended | |||||||
| March 31, | |||||||
| (In thousands) | 2024 | 2023 | |||||
| Diluted earnings per share, as reported | $ | (0.05 | ) | $ | 0.48 | ||
| Provision for litigation, net | (0.00 | ) | — | ||||
| Amortization of intangibles | 0.22 | 0.05 | |||||
| Merger and acquisition-related costs/licensing | 0.41 | 0.01 | |||||
| Acquisition of in-process research and development | 0.09 | — | |||||
| Net (gain) loss from strategic investments | 0.00 | — | |||||
| Non-cash acquisition-related foreign currency impacts | 0.08 | — | |||||
| Tax effect of adjusting items | (0.22 | ) | (0.01 | ) | |||
| Restructuring costs | 0.18 | — | |||||
| Non-GAAP diluted earnings per share | $ | 0.72 | $ | 0.53 | |||
*amounts might not add due to rounding
Non-GAAP Free Cash Flow Reconciliation Table:
| Three Months Ended | |||||||
| March 31, | |||||||
| (In thousands) | 2024 | 2023 | |||||
| Net cash provided by operating activities | $ | 52,387 | $ | 53,313 | |||
| Purchases of property and equipment | (28,568 | ) | (15,991 | ) | |||
| Free cash flow | $ | 23,819 | $ | 37,322 | |||
Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:
| Three Months Ended | Reported | Currency Impact on | Constant Currency | |||||||||||||
| March 31, | Net Sales | Current | Net Sales | |||||||||||||
| (In thousands, except percentages) | 2024 | 2023 | Growth | Period Net Sales | Growth | |||||||||||
| United States | $ | 482,927 | $ | 234,120 | 106.3 | % | $ | — | 106.3 | % | ||||||
| International | 123,739 | 42,568 | 190.7 | % | (1,460 | ) | 194.1 | % | ||||||||
| Total net sales | $ | 606,666 | $ | 276,688 | 119.3 | % | $ | (1,460 | ) | 119.8 | % | |||||
Contact:
Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
www.globusmedical.com
| Last Trade: | US$74.88 |
| Daily Change: | -0.19 -0.25 |
| Daily Volume: | 565,809 |
| Market Cap: | US$8.460B |
October 02, 2024 August 21, 2024 August 06, 2024 July 17, 2024 February 20, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
